The effect of itraconazole on the vaginal candidiasis under different immunity conditions in mice

Abstract

To study the effect of itraconazole on the vaginal candidiasis caused by Candida under different immunity conditions, the fungal vaginitis model was established in female ICR mice by intravaginal inoculation of suspension of C. albicans after the animal had been pretreated with estradiol or dexamethasone. Mice were divided at random into different groups and then treated with itraconazole or IFN-γ given by gastrogavage. The burden of the fungus in the vaginal lavage fluids in the mice of the different groups was measured dynamically at different time points after the beginning of the drug treatment. The difference in the effect of itraconazole on the vaginal candidiasis between normal immune system group (group A) and control group (group D) was statistically significant (P<0.01). The difference in the efficacy of itraconazole among immunosuppressed group (group E), immuno-regulated group (group F) and the control group (group G) was statistically significant (P<0.01). But on the 5th, 6th, 7th, 9th, 11th day after the inoculation the average level of colony forming unit (CFU) of groups A, E and F showed no statistically significant difference (P>0.05). It is concluded that the efficacy of itraconazole in the treatment of the vaginal candidiasis under different immunity conditions (groups A, E and F) in mice were all good, but there was no difference in the anti-fungal effect of itraconazole among the three groups.

Keywords

C. albicans / vaginal lavage / murine model / itraconazole / immunosuppressed / IFN-γ

References

[1] YuanH. W., GuanG. H.. A clinical and mycological observation of the effects on the treatment of vaginal candidiasis with sporanox and fluconazole. Chin J Derm Venereol, 2003, 17(1): 69-70

[2] PierardG. E., ArreseJ. E., De donckerP.. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad dermatol, 1995, 32(3): 429-435

[3] WhiteT. C., MarrK. A., BowdenR. A.. Clinical, cellular, and molecular factors that contribute toantifungal drug resistantce. Clin Microbio Rev, 1998, 11(2): 382-402

[4] EckertL. O., HawesS. E., StevensC. E., et al.. Vulvovaginal candidiasis: clinical manifestations, risk factors, managemental algorithm. Obstet Gynecol, 1998, 92(5): 757-765

[5] GhalebM., HamadM., Abu-ElteenK. H.. Vaginal T lymphocyte population kinetics during experimental vaginal candidosis: evidence for a possible role of CD8+ T cells in protection against vaginal candidosis. Clin Exp Immunol, 2003, 131(1): 26-33

[6] BernardisF., SantoniG., BoccaneraM., et al.. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albican. Infect Immunity, 2000, 68(6): 3297-3304